IMVT
HEALTHCAREImmunovant Inc
AI Insight
What's Moving IMVT Today?
No stock-specific AI insight has been generated for IMVT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.32$38.90
$37.62
Fundamentals
Market Cap$7.8B
P/E Ratio—
EPS$-2.77
Dividend Yield—
Dividend / Share—
ROE-64.8%
Profit Margin—
Debt / Equity—
Trading
Volume922K
Avg Volume (10D)—
Shares Outstanding205.3M
IMVT News
29 articles- Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?Yahoo Finance·Jun 19, 2026
- Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsightYahoo Finance·Jun 18, 2026
- Immunovant Stock Gains 12.4% in a Month: What's Driving It?Yahoo Finance·Jun 12, 2026
- Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial CommentaryYahoo Finance·Jun 5, 2026
- H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial DataYahoo Finance·Jun 2, 2026
- A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45Moomoo·May 31, 2026
- Immunovant(IMVT.US) Director Sells US$7.44 Million in Common StockMoomoo·May 30, 2026
- Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold RatingYahoo Finance·May 28, 2026
- This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 MillionMotley Fool·May 24, 2026
- This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last QuarterMotley Fool·May 24, 2026
- What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock SurgeMotley Fool·May 23, 2026
- Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyMotley Fool·May 23, 2026
- IMVT's Q4 loss wider than expected, stock up 35% on strong study dataMSN·May 23, 2026
- Immunovant (IMVT) Is Up 24.2% After Axing Batoclimab To Back IMVT-1402 Autoimmune Pivot - Has The Bull Case Changed?Simply Wall Street·May 23, 2026
- [Form 4] Immunovant, Inc. Insider Trading ActivityStock Titan·May 22, 2026
- Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?Yahoo Finance·May 22, 2026
- Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment TrialYahoo Finance·May 21, 2026
- 2 Biotech Stocks Are Surging Today Thanks to This Arthritis DrugYahoo Finance·May 20, 2026
- These Two Biotech Stocks Rocketed — And One Just Broke OutYahoo Finance·May 20, 2026
- Sector Update: Healthcare Stocks Mixed Late AfternoonYahoo Finance·May 20, 2026
- Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.08, Implies 64% UpsideTradingView·May 20, 2026
- Immunovant Q4 Earnings Call HighlightsMarketbeat·May 20, 2026
- Immunovant Shares Rally on Positive Trial Results Despite Earnings Miss (IMVT)Advfn·May 20, 2026
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business UpdateYahoo Finance·May 20, 2026
- Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026Yahoo Finance·May 20, 2026
- Immunovant Inc stock (US45258Q1058): focus on upcoming earnings after trial setbackAD HOC NEWS·May 19, 2026
- Immunovant stock (US45258Q1058): investors eye upcoming earnings date and autoimmune pipelineAD HOC NEWS·May 16, 2026
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
- Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)GlobeNewswire Inc.·Apr 2, 2026
All 29 articles loaded
Price Data
Open$37.36
Previous Close$38.10
Day High$38.90
Day Low$37.36
52 Week High$38.90
52 Week Low$14.32
52-Week Range
$14.32$38.90
$37.62
Fundamentals
Market Cap$7.8B
P/E Ratio—
EPS$-2.77
Dividend Yield—
Dividend / Share—
ROE-64.8%
Profit Margin—
Debt / Equity—
Trading
Volume922K
Avg Volume (10D)—
Shares Outstanding205.3M
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—